Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Frailty × Temozolomide × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 11 Pheochromocytoma 5 Carcinoma, Neuroendocrine 5 Somatostatinoma 3 Paraganglioma 3 Zollinger-Ellison Syndrome 2 Vipoma 2 Pituitary Neoplasms 2 Carcinoma, Medullary 2 Carcinoid Tumor 2 Small Cell Lung Carcinoma 1 Prolactinoma 1 Pancreatic Neoplasms 1 Non functioning pancreatic endocrine tumor 1 Multiple Endocrine Neoplasia Type 2b 1 Multiple Endocrine Neoplasia Type 2a 1 Multiple Endocrine Neoplasia Type 1 1 Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms 1 Lung Neoplasms 1 Insulinoma 1 Growth Hormone-Secreting Pituitary Adenoma 1 Glucagonoma 1 Gastroenteropancreatic Neuroendocrine Tumors 1 Gastro-enteropancreatic neuroendocrine tumor 1 Gastrinoma 1 Frailty 1 Extrapancreatic Neuroendocrine Tumor 1 Central Nervous System Neoplasms 1 Carcinoma, Merkel Cell 1 Adrenal Cortex Neoplasms 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05554003 2024-11-18

MeTe

European Institute of Oncology

Phase 2 Recruiting

Frailty, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡